We previously demonstrated the ability of AT1 blockers to increase the expression of both vascular endothelial growth factor (VEGF) and brain derived neurotrophic factor (BDNF) at 24 hours after stroke in normotensive animals, and this was associated with increased vascular density and improved outcome at 7 days [3]. Here, AGTR1 is linked to stroke disorder.